期刊
MOLECULAR ONCOLOGY
卷 4, 期 1, 页码 19-37出版社
WILEY
DOI: 10.1016/j.molonc.2009.10.003
关键词
Targeted therapies; Imatinib treatment; Chronic myelogenous leukemia; Activation of downstream RTK effectors
类别
资金
- Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom
This review analyzes the state of the art of targeted therapies for several tumors, starting from the paradigmatic example of Imatinib treatment in chronic myelogenous leukemia (CML). We discuss how rare tumors can be models for various mechanisms of receptor tyrosine kinase (RTK) activation, and provide the opportunity to develop new therapies also for more common cancer types. We discuss the activation of the downstream RTK effectors as further targets for therapies in colorectal cancer. Finally, we highlight how a novel multidimensional approach which adds an in silico dimension to the in vitro and in vivo approach, can predict clinical results. (C) 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据